drugset / Trial / NCT04918914
Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment
NaSingle-groupOpen-labelTreatment
Summary
Abstract Background: Clinicians in pulmonary critical care medicine and critical care medicine considered dapsone administration to treat SARS-CoV-2 inflammasome. Dapsone is useful in the molecular regulation of Nod-like receptor family pyrin domain-containing 3 (NLRP3). Objective: To study the targeting of NLRP3 itself or up-/downstream factors of the NLRP3 inflammasome by dapsone must be responsible for its observed preventive effects, functioning as a competitor. Methods: Patients who were on standard COVID-19 therapy are also after obtaining off label uses and explanation of side effects are started on dapsone 100-200 mg daily along with Cimetadine 400 mg three times daily.
Timeline
- Start
- 2020-10-18
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapsone | Small molecule | 100 mg | Oral |
| Subject | Dapsone | Small molecule | 200 mg | Oral |
| Background | Cimetadine | Unknown | 400 mg | Oral |